Ligand Pharmaceuticals (LGND) Interest Expenses (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Interest Expenses data on file, last reported at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 1618.57% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (up 296.38% YoY), and the FY2025 full-year result was $31.7 million, down 55.74% from the prior year.
• Interest Expenses advanced to $14.9 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $14.9 million in Q3 2025 to a low of $1000.0 in Q3 2023.
• A 5-year average of $2.7 million and a median of $789000.0 in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses tumbled 99.7% in 2023 and jumped 74000.0% in 2024, its largest moves.
• Tracing LGND's Interest Expenses over 5 years: stood at $660000.0 in 2022, then slumped by 80.15% to $131000.0 in 2023, then surged by 574.05% to $883000.0 in 2024, then jumped by 400.11% to $4.4 million in 2025, then surged by 237.41% to $14.9 million in 2026.
• Business Quant data shows LGND's Interest Expenses at $14.9 million in Q1 2026, $4.4 million in Q4 2025, and $14.9 million in Q3 2025.